Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

628 questions · 651 findings · 39 reviews · Skin

No studies found 167 · 25.7%GRADE not reported 47 · 7.2%Very low 80 · 12.3%Low 139 · 21.4%Moderate 174 · 26.7%High 44 · 6.8%

Ustekinumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Ustekinumab showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (low certainty).

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis

It is very uncertain whether guselkumab changes proportion of participants cleared or almost cleared compared with placebo (very low certainty).

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

Guselkumab showed no clear difference in proportion of participants with adverse effects serious or severe… compared with placebo (low certainty).

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Guselkumab probably leads to higher proportion of participants achieving a 50% reduction in disease… compared with placebo (moderate certainty).

1 finding from 1 review

Guselkumab vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Secukinumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

Secukinumab probably leads to higher proportion of participants with adverse effects serious or severe… compared with placebo (moderate certainty).

1 finding from 1 review

Topical vitamin D derivative vs placebo

Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis

Topical vitamin D derivative may leads to higher proportion of participants cleared or almost cleared in the short… compared with placebo (low certainty).

1 finding from 1 review

Secukinumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review